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The subchronic (90-day) toxicity of a ‘‘core’’ version of EPG was assessed in rats. Crl:CD-1(ICR)BR rats
(70/sex) received diets containing a constant level of 5% EPG (w/w) or adjusted to deliver 0 (control),
0.5, 1, or 2 g/kg of body weight/day (g/kg bw/day). Subsets of animals from each group (20/sex) were
evaluated after 30 days (interim sacriﬁce); the remainder after 90 days. EPG intake at all dose levels
was associated with lower mean liver vitamin E levels; liver vitamin A and serum vitamin D were also
lower, but less consistently. Animals given 5% EPG had higher fecal output (males) and cholesterol (males
and females) without corresponding changes in serum cholesterol. Urinary pH was also mildly lower in
males given 5% EPG. However, detailed evaluation of general health and assessment of blood, organs and
tissues showed no evidence that EPG administration compromised the nutritional requirements of the
animals, caused a state of fat-soluble vitamin deﬁciency, or caused‘ toxicity to any organ system. Based
on the results of this study, it was not possible to establish a no-observable-effect level (NOEL). The pos-
sible effect of EPG on vitamin levels in the absence of any clinical signs of deﬁciency was not considered
‘‘adverse’’ per se. As such, the 2 g/kg and 5% EPG level were considered to represent a no-observable-
adverse-effect levels (NOAELs).
 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/3.0/).1. Introduction
Esteriﬁed propoxylated glycerols (EPGs) represent a family of
fat- and oil-like substances, resembling triglycerides in structure
and appearance, but modiﬁed to prevent or limit their digestion
when consumed in food. They consist of multiple propylene glycol
units inserted between the glycerol and fatty acid moieties of fats
and oils. Their poor absorption results in a low- to no-calorie pro-
ﬁle when substituted for fat in the diet.
The present study examined safety of a hydrogenated version of
EPG that is considered the ‘‘core’’ version (H-EPG-05 HR/SO 9:1)2 inrats following administration in the feed for up to 90 days
(13 weeks).
2. Materials and methods
This study was sponsored by ARCO Chemical Company, Newton
Square, Pennsylvania, and conducted at Hazelton Wisconsin, Inc.,
Madison, Wisconsin from December 11, 1991 to December 17,
1992 (In-Life testing from March 4, 1992 through June 10, 1992),
in compliance with the Principles of Good Laboratory Practice
(GLP) regulations of the United States Food and Drug Administra-
tion (FDA) and the Organization for Economic Cooperation Devel-
opment (OECD).
2.1. Animals
Male and female Crl:CD(SD)BR VAF/Plus rats (approximately
36 days old at initiation of treatment) were obtained from Charles
River Laboratories (Portage, MI). Body weights at the start of the
study ranged from 147 to 193 g for males and from 116 to 162 g
for females. Ten (10) animals per sex were chosen randomly for
quality control to assess overall health (viral screen, hematology,
clinical chemistry, histopathology, etc.,); the results were within
Table 1
Group composition.
Treatment Number of animals/sex
EPGa Corn oil 30-day sacriﬁce
(Interim)
90-day sacriﬁce
(Terminal)
g/kg bw/day 0 6% (w/w) 20 50
0.5 6% (w/w) 20 50
1 6% (w/w) 20 50
2 6% (w/w) 20 50
5% (w/w) 6% (w/w) 20 50
a EPG groups were further subdivided into subsets of animals (10–20 per sex per
group) and subjected to various analyses (Table 2).
Table 2
Subgroup allocation.
Subset Sacriﬁce Number of
animals/
sex
Parameters evaluated
A 30-day 10 Hematology and clinical chemistry; body
weight and feed consumption; necropsy
exam, organ weights, and histopathology;
liver vitamins A and E; serum 25-OH
vitamin D
B 30-day 10 Body weight and feed consumption; liver,
kidney, and spleen tissue analysis for EPG
C 90-day 10 Hematology and clinical chemistry; body
weight and feed consumption; necropsy
exam, organ weights, and histopathology
D 90-day 10 Body weight and feed consumption; liver
vitamins A and E; serum 25-OH vitamin D
E 90-day 20 Body weight and feed consumption;
necropsy exam, organ weights, and
histopathology
F 7-, 30-,
90-day
10 Body weight and feed consumption; liver,
kidney, and spleen tissue analysis for EPG;
urinalysis; fecal lipids, bile acids, EPG, and
metabolites
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mate to the laboratory environment for approximately two weeks
before being stratiﬁed by body weight and allocated to ﬁve treat-
ment groups. As Table 1 illustrates, each group contained a total
of 140 animals (70/sex), 40 (20/sex) of which were sacriﬁced and
evaluated after 30 days (interim sacriﬁce).
2.2. Test article and dosing
The test material, esteriﬁed propoxylated glycerol [H-EPG-05
HR/SO 9:1; EPG (stabilized with tocopherols, including a-tocoph-
erol), lot # 753489], a ﬂaked, yellow solid material, was provided
by the sponsor. It was stored at 20 ± 10 C; prior to use, it stored
at room temperature overnight, and remained at room tempera-
ture thereafter.
EPG was incorporated in the diet at concentrations providing 0
(vehicle control), 0.5, 1, or 2 g/kg bw/day; one group received EPG
at a constant level of 5% (w/w) in the feed. The dietary concentra-
tion of 5% EPG was consistent with what is generally considered
the maximum that can be given to animals without interfering
with their nutrition status and caloric needs. Other EPG dose levels
were administered on a g/kg bw/day/day basis to achieve constant
exposure levels throughout the study.
The carrier was Modiﬁed NIH-07 Rat and Mouse Ration (Harlan
Teklad, Madison, Wisconsin). The modiﬁed diet excluded soybean
oil and a small portion of corn normally added, resulting in a fat
content between 3.1 and 3.8%; corn oil (Mazola 100% pure corn
oil, Lot No. 2321) was added at 6% (w/w). The remaining major
components were approximately 25% protein, 5% crude ﬁber, 10%
moisture, and 8% ash.
Test diets were prepared weekly to achieve the appropriate g
EPG/kg bw/day exposure level, and each concentration was pre-
pared independently. The control diet was prepared using a ribbon
mixer without heating the corn oil. The EPG/corn oil mixture was
warmed to approximately 50 C in a water bath, while stirring,
before being added to the appropriate amount of feed. The mixture
was manually mixed into a fraction of the total feed amount and
then blended in a mixer for approximately 15 min. This mixture
was then transferred to a ribbon mixer with the remaining feed
for approximately 15 min. EPG/corn oil preparations were stored
in a refrigerator (5 ± 3 C) until one day before feeding; prepared
diets were stored in feed jars at room temperature for one day
before feeding.
Homogeneity of all test diets (data not shown) was assessed by
analyzing samples (100-g) from the top, bottom, and two opposing
sides of the mixing apparatus for EPG content. The percent varia-
tion for the diet preparations ranged from 2% to 6% and from
0.4% to 10% for the 0.5 and 2 g/kg bw/day EPG preparations,
respectively.
The concentration of EPG (mean of replicate analysis) in sam-
ples stored refrigerated for 12 days and at room temperature for
9 days ranged from 98.8% to 99.6% of initial levels. For samples
stored for 3 weeks at room temperature, EPG levels ranged from95.8% to 96.4%. Frozen samples stored for 7 weeks, the EPG levels
ranged from 97.2% to 98.7% of initial levels. For samples stored
for 8 weeks refrigerated and 11 days at room temperature, the
EPG levels ranged from 93.6% to 95.9% of the initial levels. These
data demonstrate that the diet preparations were stable under
conditions of the study.
2.3. Housing
Rats were housed individually in stainless steel, screen-bottom
cages. Environmental controls for the animal room were set to
maintain 19–25 C (66–78 F), a relative humidity of 30–70%, and
a 12-h light/12-h dark cycle. Variations from these conditions were
documented and were considered to have no effect on the outcome
of the study. Feed and water were provided ad libitum. Water sam-
ples were analyzed for total dissolved solids, hardness, and speci-
ﬁed microbiological content, and for selected elements, heavy
metals, organophosphates, and chlorinated hydrocarbons. There
were no known contaminants in the feed or water that would have
interfered with this study.
2.4. Observations
Rats were assigned to ﬁve groups (0, 0.5, 1, and 2 g/kg bw/day,
5% EPG); subsets of animals were sacriﬁced after 30 days and sub-
jected to multiple evaluations, as illustrated in Table 2.
2.5. Mortality and clinical signs
Animals were observed twice daily (AM and PM) for mortality
and moribundity. Signs of poor health or abnormal behavior were
recorded. Detailed physical examinations were performed weekly.
2.6. Body weight and weight gain
Body weights were recorded for all groups (except animals peri-
odically housed in metabolism cages for fecal analyses; see below)
on the ﬁrst day of treatment, at least weekly thereafter, and at the
time of death; weekly body weight gain was calculated.
2.7. Feed consumption and EPG intake
Feed consumption was recorded once weekly; feed (and water)
consumption were measured daily during fecal collection intervals.
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an accurate feed weight value could not be obtained (e.g., acciden-
tally spilled prior to weighing).
EPG intake was calculated as g EPG per kg of body weight per
day (g/kg bw/day) based on body weights, feed consumption val-
ues, and the theoretical EPG concentrations in the feed.
2.8. Ophthalmic examination
Ophthalmic examinations were performed on all animals before
treatment initiation and during the last week of the study for ani-
mals in the control and 5% EPG groups. Pupils were dilated with
0.5% Mydriacyl, and eyes were examined by a board-certiﬁed
ophthalmologist using an indirect ophthalmoscope and a slitlamp
biomicroscope.
2.9. Hematology, clinical chemistry, and urinalysis
Hematology and serum chemistry parameters were evaluated
for 10 animals/sex/group after 30 (subset A) and 90 days (subset
C) of treatment. Animals were fasted overnight prior to blood col-
lection. Blood was collected under ketamine anesthesia from the
retro-orbital plexus for all tests except prothrombin time. For pro-
thrombin time, animals were anesthetized with sodium pentobar-
bital and samples were taken by cardiac puncture. The laboratory
staff inadvertently failed to collect blood for hematology and clin-
ical chemistry from most females at the 30-day time point.
Urinalysis was performed on a 24-h urine sample was collected
from animals of subset F (10/sex/group) after 7, 30, and 90 days of
treatment.
2.10. Liver and serum vitamins
Vitamin assays were performed on animals of subsets A and D
(10/sex) from each group at the 30- and 90-day time points.
Animals were fasted overnight and anesthetized with ketamine.
For 25-OH vitamin D analysis, blood samples from the retro-orbital
plexus were centrifuged; serum was harvested and stored in a
freezer at 20 ± 10 C. Total 25-OH Vitamin D, which included
25-OH vitamin D3 and 25-OH vitamin D2, was measured by
radioimmunoassay.
For liver vitamins A and E, subsets of animals (10/sex/group)
were anesthetized with sodium pentobarbital and weighed; the
liver was removed and a cross section of the liver (consisting of
the distal portion of each lobe) was collected, frozen in liquid nitro-
gen, and stored in a freezer at 70 ± 10 C until analysis for trans-
retinol and a-tocopherol (vitamins A and E) by high-performance
liquid chromatography (HPLC).
2.11. Tissue EPG
The liver, kidneys, and spleen of animals from subsets B and F
(10/sex) from the interim and terminal sacriﬁces (control and 5%
EPG groups only) were collected for analysis of EPG content after
30 and 90 days of treatment. Animals were anesthetized with
sodium pentobarbital, weighed, and exsanguinated. Tissues were
collected, weighed, and stored at 20 ± 10 C until analyzed using
HPLC.
2.12. Fecal analysis
Subset F of animals (10/sex) from the control and 5% EPG groups
were randomly selected for placement in metabolism cages for
monitoring daily body weights, feed and water consumption, and
fecal and urine output at various time points (7, 30, and 90 days).
These data were excluded from the group data (weekly) summa-ries and statistical analysis, and were omitted from the calculations
for dietary EPG concentrations.
During each collection period, fecal samples from each animal
were collected daily, weighed, and stored at 20 ± 10 C until ana-
lyzed. Measurements continued daily until a sufﬁcient quantity of
(pooled) fecal sample was collected (at least 25 g).
Feces were analyzed for EPG, EPG metabolites (mono- and dies-
ter; organic solvent extraction followed by solid-phase on silica
column, and HPLC using non-aqueous reverse phase (NARP) chro-
matography), cholesterol (quantitative determination by gas chro-
matography following derivatization), total fatty acids (free and
esteriﬁed; gas chromatography), and bile acids (extracts analyzed
by automated enzymatic analysis). Bile acids included primary,
secondary, and tertiary bile acids (with free 3-alpha-hydroxyl
groups) in fecal extracts.
2.13. Necropsy
Subset A of animals from the 30-day (10/sex/group) and subsets
C and E of animals from 90-day (30/sex/group) sacriﬁces were
anesthetized with sodium pentobarbital, weighed, exsanguinated,
and necropsied, along with any animal that died or was sacriﬁced
prematurely. The necropsy included gross examination of the
external surface of the body, all oriﬁces and cavities (cranial, nasal,
thoracic, abdominal, pelvic, etc.,), external and cut surfaces of the
brain and spinal cord, viscera, and cecum contents.
2.14. Organ weights
Organs weighed (when present) at scheduled necropsy
included: adrenals; brain; cecum (full and empty); heart; kidneys;
liver; ovaries with fallopian tubes; spleen; testes; and thymus.
Organ-to-body weight and organ-to-brain weight ratios were
calculated.
2.15. Histopathological examination
All lesions identiﬁed during gross examination were examined
microscopically, along with the following major organs and tissues
from subset A of animals at 30 days (10/sex) and subsets C and E of
animals from 90 days (30/sex). adrenals; aorta; brain; cecum; cer-
vix; colon; duodenum; esophagus; eyes; external auditory seba-
ceous (Zymbal’s) gland; exorbital lacrimal gland; femur with
bone marrow; Harderian gland; heart; ileum (including Peyer’s
patches); jejunum; kidneys; liver; lung with airway; lymph nodes
(submaxillary and mesenteric); mammary glands (females only);
muscle (thigh); nasal turbinates; ovaries and fallopian tubes; pan-
creas; pituitary; prostate; rectum; salivary glands (submaxillary);
sciatic nerve; seminal vesicles; skin; spinal cord (cervical, mid-tho-
racic, lumbar); spleen; sternum; stomach; testes with epididymi-
des; thymus; thyroids with parathyroid; tongue; trachea; urinary
bladder; uterus; and vagina. Tissues were preserved in 10% phos-
phate-buffered formalin (or other suitable ﬁxative), processed,
embedded, sectioned, stained with hematoxylin and eosin, and
examined by a qualiﬁed pathologist.
All tissues from the control and 5% EPG groups were examined;
in animals from the 0.5, 1, and 2 g/kg bw/day groups, histopathol-
ogical examination was limited to any macroscopic lesions, gastro-
intestinal tract (cecum, color, duodenum, esophagus, ileum,
jejunum, rectum, and stomach), lungs, liver, and kidneys.
2.16. Statistical analyses
Levene’s test (Levene, 1960) was done to test for variance
homogeneity. In the case of heterogeneity of variance at p 6 0.05,
rank transformations were used to stabilize the variance. Analysis
Table 3
Male body weights (g).
Week N EPG in diet
g/kg bw/day 5%
0 0.5 1 2
1 60 168.1 ± 8.43 168.3 ± 9.31 170.7 ± 9.46 167.5 ± 9.00 166.3 ± 9.92
2 60 231.4 ± 14.40 231.7 ± 14.33 230.2 ± 14.16 229.0 ± 13.74 230.6 ± 14.99
3 60 289.7 ± 19.36 289.6 ± 22.03 286.7 ± 19.60 284.3 ± 19.46 284.4 ± 19.60
4 60 336.7 ± 23.76 336.1 ± 28.19 333.6 ± 24.50 332.1 ± 24.52 336.2 ± 24.78
5 50 374.8 ± 29.20 372.3 ± 34.58 367.5 ± 28.55 370.8 ± 29.57 369.9 ± 27.73
6 40 406.7 ± 30.17 402.9 ± 42.27 399.8 ± 33.06 402.7 ± 35.61 400.8 ± 30.49
7 40 431.1 ± 36.72 430.1 ± 48.22 424.7 ± 37.28 431.8 ± 38.34 427.9 ± 33.88
8 40 453.3 ± 38.76 449.3 ± 51.92 441.9 ± 41.53 453.9 ± 41.37 450.3 ± 36.67
9 40 472.3 ± 42.21 467.5 ± 55.77 459.2 ± 43.60 472.7 ± 44.76 467.0 ± 40.13
10 40 493.1 ± 44.00 488.2 ± 59.50 477.2 ± 45.62 487.1 ± 46.00 482.2 ± 42.58
11 40 511.9 ± 48.49 507.0 ± 63.52 498.7 ± 48.38 508.1 ± 50.84 500.5 ± 47.28
12 40 527.5 ± 53.17 521.9 ± 66.52 512.8 ± 50.92 522.9 ± 52.76 517.3 ± 49.26
13 40 541.7 ± 56.64 536.9 ± 70.76a 524.8 ± 51.80 537.6 ± 55.33 531.1 ± 50.52
14 40 552.9 ± 59.52 549.6 ± 72.47a 538.5 ± 55.06 547.9 ± 54.99 541.2 ± 53.96
Values represent mean ± SD, unless otherwise speciﬁed.
a Number of animals (N) was 39.
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or rank-transformed data. If the ANOVA was signiﬁcant, Games and
Howell Modiﬁed Tukey–Kramer test (Games and Howell, 1976)
was used for pairwise comparisons between groups. As already
mentioned, statistical analysis of weekly body weight, body weight
gain, and feed consumption data did not include values from ani-
mals periodically housed in metabolism cages for fecal analyses.
One-way ANOVA was used to analyze body weights (excluding
weekly body weight values for females; see below); cumulative
body weight gains; feed consumption, liver and serum vitamin lev-
els; fecal weights; fecal assays; water consumption; clinical chem-
istry and hematology values (except red blood cell morphology);
urine pH, volume, and speciﬁc gravity; organ weights; and
organ-to-body weight percentages. Group comparisons were eval-
uated at the 5% two-tailed probability level.
One way analysis of covariance [ANCOVA (Winer, 1971b) was
used to analyze weekly female body weights, with body weight
after the ﬁrst week as the covariate, because ANOVA showed sig-
niﬁcance for the 0.5 g/kg bw/day vs. 5% EPG females at this time
point. Games and Howell Modiﬁed Tukey–Kramer test was used
for pairwise comparisons between groups when ANCOVA was sig-
niﬁcant. Group comparisons were evaluated at the 5% two-tailed
probability level.
For liver and serum vitamin levels, when ANOVA was signiﬁ-
cant, Dunnett’s t-test (Dunnett, 1964) was also used for pairwiseTable 4
Female body weights (g).
Week N EPG in diet
g/kg bw/day
0 0.5
1 60 140.5 ± 9.07 140.8 ± 9.12
2 60 168.8 ± 10.47 168.6 ± 12.36
3 60 193.2 ± 13.56 192.1 ± 15.68
4 60 213.6 ± 17.03 213.5 ± 20.29
5 60 229.3 ± 19.94 230.7 ± 25.16
6 40 247.0 ± 21.92 243.2 ± 28.92
7 40 256.3 ± 23.66 253.0 ± 29.66
8 40 265.9 ± 26.91 265.1 ± 32.63
9 40 276.9 ± 27.66 274.2 ± 32.32
10 40 288.9 ± 31.02 285.6 ± 33.69
11 40 297.2 ± 33.35 292.3 ± 35.12
12 40 305.1 ± 35.16 302.5 ± 35.12
13 40 306.5 ± 35.42 304.8 ± 36.29
14 40 307.6 ± 36.15 309.3 ± 38.43
Values represent mean ± SD, unless otherwise speciﬁed.comparisons between treated and control groups, and these group
comparisons were evaluated at the 5% one (left)-tailed probability
level.
3. Results
Unless otherwise stated, all differences are based on compari-
sons with the control group
3.1. Mortality and clinical signs
One male from the 1 g/kg bw/day group was sacriﬁced in mor-
ibund condition on Day 22, the apparent result of a broken nose.
One male from the 0.5 g/kg bw/day group died during Week 12.
All other animals survived until respective scheduled sacriﬁce.
Clinical signs noted in this study were consistent with those
commonly seen in rats of this strain and age; the incidence was
comparable between treated and control animals (data not
shown).
3.2. Body weights and weight gain
Weekly body weight values for males and females are summa-
rized in Tables 3 and 4, respectively. Mean body weights and body
weight gains were comparable across all groups throughout the5%
1 2
138.7 ± 9.25 138.6 ± 8.93 136.1 ± 8.55
165.4 ± 13.58 167.1 ± 12.54 164.2 ± 11.71
191.2 ± 16.75 192.4 ± 17.26 188.0 ± 15.76
210.6 ± 21.17 213.5 ± 20.18 209.6 ± 18.50
224.9 ± 24.20 226.3 ± 23.06 225.0 ± 21.43
237.8 ± 27.15 244.7 ± 25.38 242.3 ± 24.11
247.9 ± 28.79 257.0 ± 27.44 255.5 ± 24.78
258.0 ± 32.50 267.9 ± 29.30 266.9 ± 25.93
267.9 ± 33.06 276.3 + 30.14 275.9 ± 27.09
278.3 ± 33.86 286.3 + 31.92 285.0 ± 29.91
285.2 ± 35.67 294.3 ± 34.37 293.7 ± 32.58
293.7 ± 37.47 301.4 ± 5.82 300.0 ± 33.64
299.4 ± 37.84 304.9 ± 36.97 306.8 ± 35.25
303.8 ± 40.03 313.4 ± 39.47 305.8 ± 35.83
Table 5
Feed consumption (g) among males.
Week EPG in diet
g/kg bw/day 5%
0 0.5 1 2
1 157.7 ± 14.20 159.2 ± 14.61 160.5 ± 12.47 159.5 ± 12.81 167.2 ± 12.96*
N = 59 N = 60 N = 59 N = 58 N = 59
2 169.3 ± 16.24 171.4 ± 19.18 170.4 ± 15.16 169.4 ± 15.43 177.4 ± 15.72
N = 55 N = 59 N = 57 N = 59 N = 56
3 178.9 ± 15.10 176.8 ± 18.68 179.7 ± 13.79 178.0 ± 16.83 182.3 ± 14.24
N = 53 N = 50 N = 47 N = 56 N = 44
4 181.8 ± 18.70 179.2 ± 21.34 180.3 ± 17.54 181.7 ± 17.60 189.2 ± 14.30
N = 42 N = 42 N = 40 N = 46 N = 39
5 181.2 ± 19.68 176.2 ± 22.22 175.0 ± 14.35 181.0 ± 19.79 186.9 ± 13.05
N = 34 N = 35 N = 28 N = 34 N = 27
6 184.9 ± 21.86 184.2 ± 22.14 183.3 ± 13.65 188.4 ± 18.05 188.0 ± 12.44
N = 34 N = 35 N = 29 N = 34 N = 33
7 181.3 ± 19.24 178.7 ± 21.99 181.8 ± 20.42 185.3 ± 17.21 191.2 ± 13.50
N = 34 N = 31 N = 28 N = 34 N = 28
8 182.9 ± 20.77 180.9 ± 21.12 171.8 ± 17.42 182.3 ± 15.96 185.7 ± 20.50
N = 35 N = 32 N = 33 N = 31 N = 33
9 187.1 ± 19.23 190.2 ± 20.40 180.3 ± 16.67 191.4 ± 19.67 191.7 ± 17.76
N = 39 N = 38 N = 37 N = 36 N = 36
10 183.1 ± 20.22 186.1 ± 22.90 177.7 ± 19.10 186.3 ± 19.48 188.8 ± 22.64
N = 39 N = 37 N = 35 N = 36 N = 34
11 184.2 ± 25.09 186.0 ± 22.79 180.7 ± 22.46 187.9 ± 16.50 185.5 ± 19.05
N = 39 N = 35 N = 35 N = 35 N = 34
12 183.4 ± 20.45 185.9 ± 22.40 184.2 ± 18.38 188.4 ± 17.51 190.6 ± 18.02
N = 39 N = 36 N = 35 N = 39 N = 38
13 178.6 ± 20.27 183.5 ± 21.42 181.2 ± 19.62 184.0 ± 17.70 185.4 ± 19.45
N = 39 N = 35 N = 37 N = 36 N = 36
Values represent mean ± SD, unless otherwise speciﬁed.
* Statistically signiﬁcant (p 6 0.05).
Table 6
Feed consumption (g) among females.
Week EPG in diet
g/kg bw/day 5%
0 0.5 1 2
1 120.5 ± 16.72 120.8 ± 16.62 115.6 ± 15.35 119.9 ± 13.37 118.9 ± 16.75
N = 44 N = 40 N = 42 N = 35 N = 47
2 119.5 ± 11.13 117.1 ± 13.04 114.5 ± 15.64 124.3 ± 14.61 119.9 ± 19.66
N = 41 N = 39 N = 34 N = 34 N = 35
3 123.8 ± 13.86 127.0 ± 18.22 127.3 ± 20.31 130.8 ± 17.27 127.1 ± 16.64
N = 38 N = 38 N = 39 N = 31 N = 37
4 128.0 ± 14.47 126.6 ± 17.77 119.4 ± 20.95 128.6 ± 17.33 124.5 ± 16.89
N = 37 N = 35 N = 25 N = 28 N = 30
5 127.4 ± 14.77 128.5 ± 28.15 117.2 ± 18.23 130.0 ± 21.13 128.1 ± 17.60
N = 25 N = 24 N = 20 N = 19 N = 19
6 136.2 ± 23.54 132.6 ± 16.37 131.9 ± 22.17 137.4 ± 13.96 131.5 ± 15.34
N = 21 N = 23 N = 19 N = 22 N = 18
7 129.7 ± 14.37 128.8 ± 14.13 126.4 ± 20.22 137.4 ± 21.28 131.9 ± 14.64
N = 23 N = 20 N = 20 N = 14 N = 19
8 136.2 ± 15.67 133.3 ± 15.84 121.2 ± 16.60* 131.6 ± 12.88 133.9 ± 16.59
N = 28 N = 27 N = 19 N = 22 N = 24
9 136.3 ± 16.86 136.0 ± 15.74 132.1 ± 21.82 136.1 + 14.35 138.3 ± 19.68
N = 26 N = 30 N = 26 N = 21 N = 22
10 135.6 ± 27.49 130.7 ± 17.33 125.8 ± 18.04 136.4 + 19.56 134.6 ± 18.57
N = 32 N = 32 N = 25 N = 25 N = 22
11 128.7 ± 13.83 134.2 ± 13.09 124.7 ± 15.72 127.2 ± 16.57 130.1 ± 15.00
N = 26 N = 28 N = 25 N = 25 N = 22
12 130.1 ± 15.64 129.3 ± 12.40 128.8 ± 27.12 132.1 ± 19.14 125.5 ± 12.84
N = 26 N = 32 N = 28 N = 26 N = 26
13 111.7 ± 14.27 122.6 ± 13.16 117.8 ± 21.67 119.0 ± 17.86 110.1 ± 14.04
N = 26 N = 32 N = 25 N = 26 N = 22
Values represent mean ± SD, unless otherwise speciﬁed.
* Statistically signiﬁcant (p 6 0.05).
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Table 8
Hematology values for males.
EPG Na RBC (106/lL) HGB (g/dL) HCT (%) MCV (f/L) MCH (pg) MCHC (g/dL) PLT (103/lL) PT (sec) WBC (103/lL)
30-Day
0 g/kg bw/day 9 7.02 ± 0.421 14.3 ± 1.03 40.7 ± 2.59 58 ± 1.3 20.3 ± 0.63 35.1 ± 0.73 994 ± 84.3 17.0 ± 1.08 10.4 ± 1.89
0.5 10 6.95 ± 0.690 14.3 ± 1.12 41.0 ± 2.82 59 ± 2.6 20.6 ± 0.69 34.8 ± 0.46 908 ± 232.5 17.4 ± 2.03 9.1 ± 3.16
1 10 6.96 ± 0.443 14.1 ± 0.92 40.8 ± 2.31 59 ± 2.8 20.2 ± 0.92 34.5 ± 0.62 944 ± 85.5 17.1 ± 1.14 8.4 ± 2.31
2 10 7.01 ± 0.357 14.3 ± 0.85 41.4 ± 2.64 59 ± 2.3 20.4 ± 0.69 34.6 ± 0.70 927 ± 91.5 17.6 ± 2.37 10.6 ± 2.47
5% 10 6.97 ± 0.221 14.6 ± 0.54 41.8 ± 1.24 60 ± 2.1 20.9 ± 0.82 34.9 ± 0.52 995 ± 109.2 17.8 ± 1.88 9.2 ± 2.54
90-Day
0 g/kg bw/day 10 8.76 ± 0.178 15.4 ± 0.65 44.2 ± 1.97 51 ± 1.8 17.6 ± 0.64 34.8 ± 0.23 952 ± 111.8 16.9 ± 1.24 10.1 ± 2.70
0.5 10 8.46 ± 0.406 15.3 ± 0.98 44.1 ± 2.33 52 ± 1.4 18.1 ± 0.74 34.7 ± 0.61 884 ± 88.1 16.7 ± 1.74 9.1 ± 2.88
1 10 8.72 ± 0.457 15.7 ± 0.50 45.3 ± 1.64 52 ± 2.1 18.1 ± 0.89 34.7 ± 0.50 893 ± 64.0 17.7 ± 1.02 8.7 ± 1.37
2 10 8.48 ± 0.518 15.5 ± 0.75 44.3 ± 2.38 52 ± 0.8 18.3 ± 0.38 35.0 ± 0.47 961 ± 103.0 16.5 ± 0.93 9.4 ± 2.94
5% 10 8.52 ± 0.262 15.7 ± 0.61 45.1 ± 1.66 53 ± 2.1 18.5 ± 0.89 34.9 ± 0.73 940 ± 109.4 17.5 ± 1.33 8.4 ± 1.77
N NRBC
(/100 WBC)
COR WBC
(103/lL)
N-SEG
(103/lL)
N-BAND
(103/lL)
LYMPH
(103/lL)
MONO
(103/lL)
EOSIN
(103/lL)
BASO
(103/lL)
30-Day
0 g/kg bw/day 9 0 ± 0.7 10.4 ± 1.91 1.8 ± 1.40 0 8.4 ± 1.41 0.2 ± 0.16 0.0 ± 0.04 0
(17%) (81%) (2%) (0%)
0.5 10 0 ± 0.4 9.1 ± 3.16 1.6 ± 0.69 0 7.3 ± 2.87 0.1 ± 0.11 0.0 ± 0.08 0
(19%) (80%) (1%) (0%)
1 10 0 ± 0.4 8.4 ± 2.32 1.4 ± 0.62 0 6.8 ± 2.11 0.1 ± 0.14 0.1 ± 0.05 0
(17%) (81%) (1%) (1%)
2 10 0 ± 0.5 10.5 ± 2.46 1.8 ± 1.05 0 8.4 ± 1.87 0.3 ± 0.22 0.1 ± 0.08 0
(16%) (81%) (3%) (1%)
5% 10 0 ± 0.5 9.1 ± 2.54 1.4 ± 0.99 0 7.6 ± 2.19 0.1 ± 0.09 0.0 ± 0.05 0
(16%) (83%) (1%) (0%)
90-Day
0 g/kg bw/day 10 0 ± 0.3 10.1 ± 2.70 1.3 ± 0.73 0 8.5 ± 2.61 0.2 ± 0.23 0.1 ± 0.09 0
(14%) (84%) (2%) (1%)
0.5 10 0 ± 0.0 9.1 ± 2.88 1.8 ± 0.93 0 7.2 ± 2.65 0.1 ± 0.10 0.1 ± 0.08 0
(20%) (78%) (1%) (1%)
1 10 0 ± 0.0 8.7 ± 1.37 1.5 ± 0.96 0 7.1 ± 1.21 0.1 ± 0.12 0.1 ± 0.08 0
(16%) (82%) (1%) (1%)
2 10 0 ± 0.3 9.4 ± 2.94 1.9 ± 1.55 0 7.2 ± 2.00 0.3 ± 0.25 0.1 ± 0.05 0
(19%) (78%) (3%) (1%)
5% 10 0 ± 0.0 8.4 ± 1.77 1.4 ± 0.65 0 6.8 ± 1.91 0.2 ± 0.28 0.1 ± 0.07 0
(18%) (80%) (2%) (1%)
Values represent mean ± SD, unless otherwise speciﬁed.
RBC: red blood cell count; HGB: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin
concentration; PLT: platelet count; PT: prothrombin time; WBC: white blood cell count; NRBC: nucleated red blood cell count; CORWBC: corrected white blood cell count; N-
SEG: segmented neutrophil count; N-BAND: band neutrophil count; LYMPH: lymphocyte count; MONO: monocyte count; EOSIN: eosinophil count; BASO: basophil count.
a Number of animals (N) as indicated, except for the following: PT at 30 days, N = 7, 9, 5, 7, and 7 in 0, 0.5, 1, 2 g/kg bw/day and 5% groups, respectively; PT at 90 days, N = 8,
9, 8, and 9 in the 0, 0.5, 2 g/kg bw/day, and 5% groups, respectively.
Table 7
Average EPG intake (g/kg bw/day).
Target EPG
concentration
Male Female
Week 1 Week 4 Week 13 Overall weeks 1–13 Week 1 Week 4 Week 13 Overall weeks 1–13
g/kg bw/day 0.5 0.364 ± 0.021 0.473 ± 0.027 0.496 ± 0.033 0.47 0.466 ± 0.045 0.501 ± 0.044 0.468 ± 0.543 0.487
1 0.732 ± 0.032 0.946 ± 0.048 0.984 ± 0.052 0.945 0.917 ± 0.084 0.981 ± 0.072 0.911 ± 0.100 0.97
2 1.468 ± 0.071 1.893 ± 0.087 1.911 ± 0.124 1.882 1.849 ± 0.137 1.969 ± 0.163 1.816 ± 0.169 1.951
5% 6.028 ± 0.261 3.838 ± 0.184 2.436 ± 0.119 3.652 5.676 ± 0.769 4.163 ± 0.338 2.609 ± 0.265 4.024
Values represent mean ± SD, unless otherwise speciﬁed.
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smaller body weight gains among males from the 1 g/kg bw/day
of EPG group (59.5 g vs. 63.2 g in control males) at Week 1 (data
not shown) and was considered incidental to EPG treatment.
3.3. Feed consumption and EPG intake
Feed consumption values are summarized in Tables 5 and 6.
Compared to control, males receiving 5% EPG in the diet generally
had greater feed consumption, although statistical signiﬁcance was
evident only at Week 1. Feed intake among females was not very
different across groups (or consistently greater at 5% EPG, as it
was in males), except at Week 8, where mean feed intake in the1 g/kg bw/day group was signiﬁcantly lower than in controls.
These ﬁnding were considered within the normal range of variabil-
ity of this measurement and not related to administration of EPG.
Animals received diets intended to deliver EPG at 0.5, 1, and 2 g/
kg bw/day, or be present at a constant level of 5% (w/w). As Table 7
shows, the diets provided between 94% and 98% of the targeted
EPG amounts overall (Weeks 1–13).3.4. Ophthalmic examinations
No treatment-related ophthalmic ﬁndings were seen in control
animals or animals fed 5% EPG diets (data not shown).
Table 9
Hematology values for females.
EPG Na RBC (106/lL) HGB (g/dL) HCT (%) MCV (f/L) MCH (pg) MCHC (g/dL) PLT (103/lL) PT (sec) WBC (103/lL)
30-Day
0 g/kg bw/day 4 6.98 ± 0.377 14.5 ± 1.04 40.8 ± 2.55 58 ± 1.3 20.8 ± 0.39 35.5 ± 0.81 1040 ± 151.0 17.4 ± 1.42 8.2 ± 2.89
0.5 3 6.90 ± 0.265 13.9 ± 0.80 39.3 ± 2.26 57 ± 1.7 20.1 ± 0.55 35.3 ± 0.06 933 ± 41.6 18.0 ± 3.19 7.1 ± 1.53
1 5 6.68 ± 0.427 13.7 ± 0.61 38.4 ± 1.86 58 ± 0.9 20.5 ± 0.55 35.6 ± 0.68 974 ± 82.6 17.2 ± 1.00 6.3 ± 2.72
2 1b 6.80 ± 0.000 14.0 ± 0.00 39.3 ± 0.00 58 ± 0.0 20.6 ± 0.00 35.6 ± 0.00 1120 ± 0.00 17.1 ± 0.69 5.5 ± 0.00
5% 4 6.98 ± 0.222 13.9 ± 0.46 39.0 ± 0.99 56 ± 2.1 19.9 ± 0.73 35.6 ± 0.57 1102 ± 116.7 17.5 ± 0.78 9.4 ± 3.24
90-Day
0 g/kg bw/day 10 8.09 ± 0.486 15.5 ± 0.77 44.0 ± 2.39 54 ± 1.1 19.2 ± 0.47 35.3 ± 0.56 937 ± 137.1 18.3 ± 0.68 5.6 ± 1.53
0.5 10 8.42 ± 0.675 15.9 ± 1.26 45.4 ± 3.31 54 ± 1.2 18.9 ± 0.40 35.0 ± 0.53 841 ± 170.5 19.0 ± 1.89 5.7 ± 1.42
1 10 8.30 ± 0.529 16.0 ± 0.92 45.3 ± 2.11 55 ± 2.0 19.3 ± 0.64 35.3 ± 0.78 880 ± 166.8 18.8 ± 0.83 5.8 ± 1.96
2 10 8.39 ± 0.463 16.0 ± 0.59 45.5 ± 1.96 54 ± 1.8 19.2 ± 0.76 35.3 ± 0.60 975 ± 158.4 18.9 ± 1.05 6.4 ± 1.61
5% 10 8.60 ± 0.488 16.4 ± 1.18 46.9 ± 3.36 55 ± 1.3 19.0 ± 0.36 34.9 ± 0.68 940 ± 154.1 18.5 ± 0.81 6.6 ± 1.85
N NRBC
(/100 WBC)
COR WBC
(103/lL)
N-SEG
(103/lL)
N-BAND
(103/lL)
LYMPH
(103/lL)
MONO
(103/lL)
EOSIN
(103/lL)
BASO
(103/lL)
30-Day
0 g/kg bw/day 4 1 ± 0.5 8.1 ± 2.89 1.5 ± 1.04 0 6.4 ± 2.87 0.0 ± 0.10 0.1 ± 0.08 0
(18)% (80%) 0% (2%)
0.5 3 1 ± 1.0 7.1 ± 1.58 1.4 ± 0.74 0 5.6 ± 1.01 0.0 ± 0.00 0.0 ± 0.00 0
(20%) (80%) (0%) (0%)
1 5 3 ± 0.5 6.1 ± 2.64 1.0 ± 0.16 0 5.0 ± 2.54 0.0 ± 0.00 0.1 ± 0.09 0
(18%) (81%) (0%) (1%)
2 1b 1 ± 0.0 5.4 ± 0.00 1.0 ± 0.00 0 4.2 ± 0.00 0.1 ± 0.00 0.2 ± 0.00 0
(18%) (77%) (2%) (3%)
5% 4 2 ± 1.7 9.3 ± 3.32 1.3 ± 0.69 0 7.9 ± 3.54 0.0 ± 0.00 0.1 ± 0.19 0
(17%) (81%) (0%) (2%)
90-Day
0 g/kg bw/day 10 0 ± 0.4 5.5 ± 1.54 0.6 ± 0.28 0 4.9 ± 1.64 0.0 ± 0.10 0.0 ± 0.00 0
(12%) (87%) (1%) (0%)
0.5 10 0 ± 0.0 5.7 ± 1.42 0.8 ± 0.67 0 4.7 ± 0.87 0.0 ± 0.05 0.1 ± 0.09 0
(13%) (85%) (1%) (1%)
1 10 0 ± 0.4 5.8 ± 1.94 0.9 ± 0.58 0 4.8 ± 1.86 0.0 ± 0.04 0.0 ± 0.07 0
(17%) (82%) (0%) (1%)
2 10 0 ± 0.3 6.4 ± 1.62 1.2 ± 1.06 0 5.2 ± 1.43 0.1 ± 0.05 0.0 ± 0.05 0
(18%) (81%) (1%) (0%)
5% 10 0 ± 0.7 6.6 ± 1.85 0.8 ± 0.25 0 5.7 ± 1.79 0.0 ± 0.10 0.1 ± 0.05 0
(13%) (86%) (1%) (1%)
Values represent mean ± SD, unless otherwise speciﬁed.
RBC: red blood cell count; HGB: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin
concentration; PLT: platelet count; PT: prothrombin time; WBC: white blood cell count; NRBC: nucleated red blood cell count; CORWBC: corrected white blood cell count; N-
SEG: segmented neutrophil count; N-BAND: band neutrophil count; LYMPH: lymphocyte count; MONO: monocyte count; EOSIN: eosinophil count; BASO: basophil count.
a Number of animals (N) as indicated, except for the following: PT at 30 days, N = 9, 10, 8, 10, and 8 in 0, 0.5, 1, 2 g/kg bw/day and 5% groups, respectively; PT at 90 days,
N = 8 in each the 0 and 2 g/kg bw/day groups.
b Blood inadvertently not drawn for most 2 g/kg bw/day females at 30 days.
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The results of the clinical pathology and urinalysis are summa-
rized in Tables 8–12. No EPG treatment related differences were
observed in any parameter, except for slightly lower urine pH
among males receiving 5% EPG (30-day and 90-day time points).3.6. Liver and serum vitamins
Liver and serum vitamin assay data are summarized in Table 13.
EPG intake was associated with lower levels of Vitamin A in liver.
Mean liver vitamin A levels were generally lower among males
receiving EPG vs. control, but the differences were not statistically
signiﬁcant, except for the 5% group at the 90-day time point. Liver
vitamin A levels in females receiving EPG were also lower, reaching
statistical signiﬁcance in all groups at 30 days, but only at 1 g/kg
bw/day and greater at 90 days. Liver vitamin A levels increased
in both male and female rats receiving EPG but to a lesser degree
than observed in control rats.
EPG intake was associated with signiﬁcantly lower mean liver
vitamin E levels. The effect was observed in both males and
females, across all dietary levels in a concentration-dependent
manner, and at all time points (except in females from the 0.5 g/
kg bw/day group at 90 days).Overall, mean serum vitamin D (25-OH vitamin D, total) levels
were lower among animals receiving EPG, and considered an effect
of EPG treatment. In males, the effect appeared to be concentra-
tion-dependent, but reached statistical signiﬁcance only at 1 g/kg
bw/day and greater, and only at 90 days. In females, the difference
from control was statistically signiﬁcant only at the 5% EPG level
(both 30- and 90-day time points).3.7. Tissue EPG
Analysis of liver, kidney, and spleen tissue (control and 5% EPG
groups only) showed no evidence of EPG (Limits of detection:
1.1 lg/kg for liver, 1.7 lg/kg for kidney, and 1.0 lg/kg for spleen).3.8. Fecal analysis
The subsets of animals (10/sex) from the control and 5% EPG
groups selected for placement in metabolism cages showed no test
material-related effects on daily body weight, feed consumption,
water consumption, or urine output measurements (data not
shown). EPG administration was associated with slightly higher
mean fecal output among males compared with controls at both
30 and 90 days. However, statistical signiﬁcance was evident only
Table 10
Clinical chemistry values for males.
EPG N GLU
(mg/dL)
BUN
(mg/dL)
CREAT
(mg/dL)
T PRO
(g/dL)
ALB
(g/dL)
GLOB
(g/dL)
A/G RATIO T BILI
(mg/dL)
CHOL
(mg/dL)
TRIG
(mg/dL)
30-Day
0 g/kg bw/day 9 141 ± 15.1 19 ± 1.9 0.6 ± 0.05 6.5 ± 0.24 4.3 ± 0.28 2.3 ± 0.13 1.9 ± 0.20 0.1 ± 0.00 78 ± 13.8 108 ± 65.2
0.5 10 145 ± 14.6 21 ± 2.4 0.6 ± 0.05 6.4 ± 0.20 4.3 ± 0.14 2.1 ± 0.16 2.0 ± 0.18 0.1 ± 0.00 80 ± 14.1 131 ± 58.9
1 10 144 ± 8.4 21 ± 2.5 0.7 ± 0.04 6.4 ± 0.32 4.3 ± 0.19 2.1 ± 0.17 2.1 ± 0.15 0.1 ± 0.03 74 ± 13.0 101 ± 53.0
2 10 143 ± 6.7 20 ± 2.6 0.7 ± 0.06 6.4 ± 0.19 4.3 ± 0.15 2.1 ± 0.13 2.0 ± 0.14 0.1 ± 0.03 79 ± 15.0 98 ± 33.6
5% 10 151 ± 13.4 20 ± 1.4 0.7 ± 0.00⁄ 6.6 ± 0.33 4.5 ± 0.22 2.1 ± 0.26 2.2 ± 0.30 0.1 ± 0.03 85 ± 16.6 115 ± 70.5
90-Day
0 g/kg bw/day 10 120 ± 18.6 14 ± 1.5 0.6 ± 0.05 6.9 ± 0.23 4.5 ± 0.15 2.4 ± 0.25 1.9 ± 0.20 0.1 ± 0.03 90 ± 26.2 93 ± 46.5
0.5 10 118 ± 22.5 13 ± 1.3 0.6 ± 0.04 6.6 ± 0.38 4.3 ± 0.29 2.4 ± 0.29 1.8 ± 0.27 0.1 ± 0.03 78 ± 15.9 74 ± 24.5
1 10 129 ± 20.3 14 ± 1.3 0.6 ± 0.05 6.7 ± 0.53 4.4 ± 0.29 2.4 ± 0.36 1.9 ± 0.24 0.1 ± 0.03 86 ± 27.2 72 ± 25.3
2 10 119 ± 10.2 13 ± 1.0 0.6 ± 0.05 6.7 ± 0.33 4.4 ± 0.22 2.3 ± 0.31 1.9 ± 0.25 0.1 ± 0.06 89 ± 9.5 69 ± 39.9
5% 10 116 ± 15.2 12 ± 1.9 0.6 ± 0.06 6.6 ± 0.40 4.4 ± 0.27 2.2 ± 0.34 2.0 ± 0.30 0.1 ± 0.04 89 ± 25.9 86 ± 38.2
N HDL
(mg/dL)
LDL
(mg/dL)
AST/SGOT
(IU/L)
ALT/SGPT
(IU/L)
GGT
(IU/L)
CA
(mg/dL)
I PHOS
(mg/dL)
NA
(mmol/L)
K
(mmol/L)
CL
(mmol/L)
30-Day
0 g/kg bw/day 9 58 ± 13.5 4 ± 6.3 138 ± 26.5 50 ± 9.1 0 ± 0.4 10.2 ± 0.41 8.7 ± 0.88 147 ± 1.7 5.4 ± 0.36 107 ± 1.2
0.5 10 57 ± 9.8 1 ± 2.8 141 ± 27.2 54 ± 8.7 0 ± 0.3 10.2 ± 0.27 8.6 ± 0.54 149 ± 2.1 5.3 ± 0.32 108 ± 1.5
1 10 57 ± 10.8 2 ± 3.2 144 ± 28.6 54 ± 5.0 0 ± 0.3 10.1 ± 0.29 9.0 ± 0.46 149 ± 2.5 5.4 ± 0.15 108 ± 1.9
2 10 59 ± 12.9 2 ± 2.2 163 ± 40.7 55 ± 18.4 0 ± 0.3 10.1 ± 0.25 8.7 ± 0.73 148 ± 1.6 5.3 ± 0.24 107 ± 1.4
5% 10 64 ± 13.3 4 ± 5.1 125 ± 24.8 55 ± 9.4 0 ± 0.3 10.5 ± 0.39 8.8 ± 0.60 150 ± 2.5 5.4 ± 0.24 108 ± 2.1
90-Day
0 g/kg bw/day 10 81 ± 25.6 1 ± 1.8 160 ± 41.4 44 ± 8.0 0 ± 0.0 9.9 ± 0.32 7.1 ± 0.48 147 ± 1.9 4.9 ± 0.28 107 ± 2.3
0.5 10 70 ± 17.0 0 ± 0.6 164 ± 40.7 48 ± 15.5 0 ± 0.0 9.6 ± 0.34 7.0 ± 0.41 147 ± 1.0 4.9 ± 0.29 107 ± 1.5
1 10 79 ± 30.5 0 ± 1.6 182 ± 36.0 43 ± 6.9 0 ± 0.0 9.6 ± 0.26 7.2 ± 0.46 147 ± 1.1 5.0 ± 0.24 107 ± 1.7
2 10 81 ± 10.1 1 ± 1.8 164 ± 41.3 42 ± 6.4 0 ± 0.0 9.8 ± 0.32 6.9 ± 0.46 147 ± 1.1 4.9 ± 0.26 107 ± 1.8
5% 10 79 ± 24.0 0 ± 0.0 154 ± 28.3 40 ± 3.3 0 ± 0.0 9.6 ± 0.23 6.8 ± 0.73 147 ± 1.5 5.0 ± 0.35 109 ± 2.0
Values represent mean ± SD, unless otherwise speciﬁed.
GLU: glucose; BUN: blood urea nitrogen; CREAT: creatinine; T PROT: total protein; ALB: albumin; GLO: globulin; A/G RATIO: albumin/globulin ratio; T BILI: total bilirubin;
CHOL: cholesterol; TRIG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; AST/SGOT: aspartate aminotransferase; ALT/SGPT:
alanine aminotransferase; GGT: gamma glutamyl transferase; CA: calcium; I PHOS: inorganic phosphorus; NA: sodium; K: potassium; CL: chloride.
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other treatment-related differences were observed.
Table 14 summarizes the fecal analysis data. EPG administra-
tion was associated with higher fecal cholesterol levels for males
receiving 5% EPG vs. control at all time points (7, 30, and 90 days);
and slightly greater fecal cholesterol was also evident in females.
Differences were statistically signiﬁcant only for males given 5%
EPG.
Fecal excretion of total fatty acids was signiﬁcantly greater in
males and females receiving EPG at all time points.
There was no clear effect of EPG treatment on the excretion of
bile acids in the feces. Some statistically signiﬁcant differences
were noted, but with no consistent pattern.
Monoester, diester, and triester forms of EPG were detected in
fecal samples of males and females given 5% EPG collected at all
time intervals (data not shown). No apparent increase or decrease
in excretion of any form of EPG was noted over time. Fecal concen-
trations of the triester recovered in feces ranged from 20.1% to
21.9% (males) and 15.2% and 18.7% (females) of the amount of
EPG consumed.
3.9. Necropsy, organ weights, and histopathology
With a few exceptions at the terminal sacriﬁce (lower mean left
kidney weight, absolute and relative to brain weight in 2 g/kg bw/
day males; lower liver weight relative to body weight in 5% males),
there were no statistically signiﬁcant differences between EPG and
the control group in organ weights. Observations noted at necropsy
ﬁndings, and differences in organ weights were all considered inci-
dental to EPG administration., Similarly upon microscopic evalua-
tion of tissue, there were no observations identiﬁed as related to
EPG treatment. or histopathological ﬁndings (data not shown).4. Discussion
Dietary administration of EPG at concentrations of 0.5, 1, and
2 g/kg bw/day and 5% to rats for up to 90 days was associated with
was associated with lower levels of liver vitamin E; liver vitamin A
and serum vitamin D, the latter less consistently. Other EPG related
ﬁndings noted only at the 5% level included higher fecal output
(males) fecal cholesterol (males and females), and mildly lower
urinary pH in males.
Urinary pH level (P6.4) for males given 5% was only slightly
lower than the minimum (pH 6.5) reported for various strains of
rats (Tannehill-Gregg et al., 2009). In addition, rats receiving EPG
at the same concentrations as in this study for up to 2 years
(unpublished) did not show any effects on urine parameters,
including pH. The higher fecal cholesterol levels in animals given
5% EPG was observed in the absence of differences in serum choles-
terol. As both changes in urinary pH and fecal cholesterol were not
associated with corresponding changes in blood or tissues, they
were not considered to be toxicologically signiﬁcant.
Fecal excretion of total fatty acids was signiﬁcantly greater
among animals receiving EPG. However, this effect was not unex-
pected. Aside from the fatty acids already present in the feed (same
as control), animals receiving EPG would have consumed (and
excreted) the fatty acids that are part of the EPG molecule.
EPG intake was associated with signiﬁcantly lower mean liver
vitamin E levels, compared to control. The effect was observed in
both males and females, across all dietary levels in a concentra-
tion-dependent manner, and generally at all time points. The vita-
min E levels appeared to be maintained over time with no
additional decreases noted between 30 and 90 days. Liver vitamin
A and serum vitamin D (25-OH vitamin D, total) were also
lower than control values over the course of the study, but less
Table 11
Clinical chemistry values for females.
EPG N GLU
(mg/dL)
BUN
(mg/dL)
CREAT
(mg/dL)
T PRO
(g/dL)
ALB
(g/dL)
GLOB
(g/dL)
A/G RATIO T BILI
(mg/dL)
CHOL
(mg/dL)
TRIG
(mg/dL)
30-Day
0 g/kg bw/day 10 97 ± 11.9 13 ± 2.0 0.6 ± 0.05 6.4 ± 0.20 4.6 ± 0.24 1.8 ± 0.14 2.7 ± 0.29 0.0 ± 0.05 82 ± 16.8 18 ± 5.2
0.5 10 107 ± 13.2 13 ± 2.1 0.6 ± 0.03 6.5 ± 0.35 4.6 ± 0.28 1.9 ± 0.29 2.5 ± 0.42 0.0 ± 0.05 81 ± 15.3 26 ± 11.6
1 10 105 ± 16.2 12 ± 2.1 0.6 ± 0.06 6.4 ± 0.24 4.4 ± 0.20 1.9 ± 0.13 2.3 ± 0.18 0.1 ± 0.05 90 ± 21.1 24 ± 5.2
2 10 99 ± 8.2 14 ± 2.4 0.6 ± 0.00 6.4 ± 0.29 4.6 ± 0.25 1.9 ± 0.12 2.4 ± 0.20 0.1 ± 0.04 72 ± 15.0 23 ± 5.5
5% 10 102 ± 19.9 13 ± 2.3 0.6 ± 0.04 6.2 ± 0.24 4.4 ± 0.24 1.8 ± 0.18 2.5 ± 0.35 0.1 ± 0.07 70 ± 9.5 22 ± 7.0
90-Day
0 g/kg bw/day 10 117 ± 11.7 16 ± 2.9 0.7 ± 0.09 7.1 ± 0.54 5.1 ± 0.43 2.0 ± 0.14 2.6 ± 0.16 0.1 ± 0.05 89 ± 20.5 46 ± 14.9
0.5 10 118 ± 20.7 16 ± 2.8 0.6 ± 0.05 6.9 ± 0.54 4.9 ± 0.71 2.0 ± 0.28 2.5 ± 0.60 0.1 ± 0.06 103 ± 20.7 63 ± 35.2
1 10 107 ± 15.9 15 ± 3.5 0.7 ± 0.04 6.8 ± 0.42 4.8 ± 0.44 2.0 ± 0.33 2.5 ± 0.48 0.1 ± 0.06 85 ± 16.5 48 ± 33.2
2 10 118 ± 16.6 16 ± 2.8 0.7 ± 0.09 6.8 ± 0.32 4.9 ± 0.42 1.9 ± 0.23 2.6 ± 0.47 0.1 ± 0.06 99 ± 14.9 48 ± 21.5
5% 10 115 ± 8.4 15 ± 2.1 0.7 ± 0.09 7.0 ± 0.35 5.1 ± 0.48 1.9 ± 0.25 2.7 ± 0.64 0.1 ± 0.03 88 ± 16.5 46 ± 15.7
N HDL
(mg/dL)
LDL
(mg/dL)
AST/SGOT
(IU/L)
ALT/SGPT
(IU/L)
GGT
(IU/L)
CA
(mg/dL)
I PHOS
(mg/dL)
NA
(mmol/L)
K
(mmol/L)
CL
(mmol/L)
30-Day
0 g/kg bw/day 10 73 ± 16.4 5 ± 2.1 145 ± 41.1 34 ± 9.5 0 ± 0.0 9.7 ± 0.25 7.3 ± 0.89 146 ± 2.5 4.8 ± 0.39 105 ± 3.0
0.5 10 72 ± 13.8 4 ± 2.6 148 ± 26.9 34 ± 7.7 0 ± 0.3 9.9 ± 0.27 6.9 ± 0.73 147 ± 2.1 4.5 ± 0.20 104 ± 2.4
1 10 80 ± 21.2 4 ± 3.1 128 ± 27.7 34 ± 6.9 0 ± 0.5 9.8 ± 0.22 7.1 ± 0.43 147 ± 2.2 4.6 ± 0.34 104 ± 2.1
2 10 63 ± 12.7 4 ± 2.4 156 ± 25.7 34 ± 5.9 0 ± 0.0 9.7 ± 0.32 6.9 ± 0.95 147 ± 1.4 4.6 ± 0.27 104 ± 2.3
5% 10 61 ± 9.3 5 ± 2.1 152 ± 29.9 35 ± 4.1 0 ± 0.0 9.6 ± 0.41 7.6 ± 0.54 147 ± 2.6 4.7 ± 0.41 104 ± 2.5
Na HDL
(mg/dL)
LDL
(mg/dL)
AST/SGOT
(IU/L)
ALT/SGPT
(IU/L)
GGT
(IU/L)
CA
(mg/dL)
I PHOS
(mg/dL)
NA
(mmol/L)
K
(mmol/L)
CL
(mmol/L)
90-Day
0 g/kg bw/day 10 84 ± 21.4 0 ± 0.7 102 ± 24.6 32 ± 5.6 0 ± 0.0 10.0 ± 0.45 6.2 ± 0.75 147 ± 2.1 4.8 ± 0.54 108 ± 2.5
0.5 10 98 ± 23.2 1 ± 2.2 117 ± 12.9 37 ± 11.2 0 ± 0.0 9.9 ± 0.46 6.7 ± 1.00 146 ± 1.4 4.8 ± 0.34 108 ± 1.4
1 10 79 ± 17.4 1 ± 2.8 127 ± 40.6 35 ± 10.3 0 ± 0.0 9.7 ± 0.43 6.5 ± 0.64 146 ± 1.3 4.7 ± 0.31 109 ± 3.0
2 10 91 ± 16.4 2 ± 4.0 106 ± 14.2 37 ± 18.5 0 ± 0.0 9.9 ± 0.38 6.0 ± 0.69 146 ± 1.2 4.9 ± 0.32 108 ± 1.6
5% 10 79 ± 15.5 1 ± 3.0 125 ± 18.6 44 ± 14.4 0 ± 0.0 9.9 ± 0.22 6.4 ± 0.83 146 ± 1.4 4.9 ± 0.26 108 ± 1.4
Values represent mean ± SD, unless otherwise speciﬁed.
GLU: glucose; BUN: blood urea nitrogen; CREAT: creatinine; T PROT: total protein; ALB: albumin; GLO: globulin; A/G RATIO: albumin/globulin ratio; T BILI: total bilirubin;
CHOL: cholesterol; TRIG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; AST/SGOT: aspartate aminotransferase; ALT/SGPT:
alanine aminotransferase; GGT: gamma glutamyl transferase; CA: calcium; I PHOS: inorganic phosphorus; NA: sodium; K: potassium; CL: chloride.
a Number of animals (N) as indicated, except for the following: HDL and LDL at 90 days, N = 9 in 5% group.
Table 12
Urinalysis values.
EPG N Male Female
Volume (mL) Speciﬁc gravity pH Volume (mL) Speciﬁc gravity pH
7-Day
0 g/kg bw/day 10 10.0 ± 3.03 1.047 ± 0.0070 6.7 ± 0.26 4.8 ± 3.65 1.053 ± 0.0154a 6.3 ± 0.35a
0.5 10 10.2 ± 2.06 1.048 ± 0.0061 6.6 ± 0.21 6.4 ± 3.19 1.055 ± 0.0136 6.5 ± 0.41
1 10 11.1 ± 3.22 1.046 ± 0.0072 6.7 ± 0.26 3.6 ± 2.10 1.062 ± 0.0158 6.5 ± 0.35a
2 10 10.2 ± 4.36 1.048 ± 0.0083 6.5 ± 0.24 4.8 ± 4.17 1.066 ± 0.0222 6.4 ± 0.39
5% 10 10.2 ± 2.03 1.053 ± 0.0069 6.4 ± 0.16 5.9 ± 5.20 1.062 ± 0.0205 6.4 ± 0.33a
30-Day
0 g/kg bw/day 10 15.9 ± 6.41 1.042 ± 0.0113 7.0 ± 0.58 10.8 ± 8.13 1.046 ± 0.0203 6.6 ± 0.24
0.5 10 14.5 ± 5.23 1.047 ± 0.0104 6.8 ± 0.35 10.9 ± 6.68 1.043 ± 0.0122 6.8 ± 0.34
1 10 14.7 ± 5.74a 1.044 ± 0.0080a 7.0 ± 0.61a 5.0 ± 3.20 1.052 ± 0.0137 6.6 ± 0.24
2 10 18.6 ± 10.39 1.041 ± 0.0116 7.0 ± 0.33 7.2 ± 3.07 1.050 ± 0.0147 6.6 ± 0.34
5% 10 12.6 ± 4.86 1.047 ± 0.0069 6.4 ± 0.34* 9.6 ± 5.79 1.048 ± 0.0130 6.7 ± 0.26
90-Day
0 g/kg bw/day 10 22.3 ± 8.94 1.034 ± 0.0108 7.1 ± 0.21 15.9 ± 12.22 1.033 ± 0.0164 6.8 ± 0.35
0.5 10 19.9 ± 6.81 1.041 ± 0.0104 7.0 ± 0.37 12.9 ± 6.73 1.039 ± 0.0133 7.1 ± 0.39
1 10 17.7 ± 3.45a 1.043 ± 0.0072a 7.2 ± 0.36a 7.4 ± 5.36 1.052 ± 0.0227 6.6 ± 0.34
2 10 22.6 ± 10.11 1.039 ± 0.0113 6.8 ± 0.26 9.6 ± 6.92 1.047 ± 0.0203 6.9 ± 0.52
5% 10 20.0 ± 6.82 1.043 ± 0.0087 6.6 ± 0.24* 11.3 ± 8.19 1.048 ± 0.0233 6.6 ± 0.75
Values represent mean ± SD, unless otherwise speciﬁed.
a Number of animals (N) was 9.
* Statistically signiﬁcant (p 6 0.05).
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all EPG groups but to a lesser degree than observed in control ani-
mals. Likewise, serum vitamin D appeared to be maintained over
time but in concentrations below those observed in control ani-
mals. The biological signiﬁcance of these ﬁndings is doubtful. Otherno- or low-calorie fat and oil substitutes have been known to affect
fat-soluble nutrients. Olestra, for example, was found to decrease
(in a dose-dependent manner) liver and serum concentrations of
vitamins A and E in pigs, and was associated with lower absorption
of fat-soluble vitamins in humans without adverse effects on the
Table 14
Summary of fecal assay data.
EPG N Male Female
Cholesterol (mg/day) Total fatty acid (mg/day) Fecal bile acid (mg/day) Cholesterol (mg/day) Total fatty acid (mg/day) Fecal bile acid (mg/day)
7-Day
0 10 5.73 ± 1.200 97.6 ± 16.05 15.5 ± 3.91 4.11 ± 0.837 62.9 ± 7.17 11.7 ± 2.27
5% 10 7.77 ± 1.269* 685 ± 58.5* 15.1 ± 3.51 5.70 ± 2.140 408 ± 97.7* 9.5 ± 3.87
30-Day
0 10 4.67 ± 0.588 103 ± 16.3 29.2 ± 5.55 3.17 ± 0.994 49.8 ± 5.60 20.5 ± 4.54
5% 10 6.34 ± 0.957* 753 ± 82.4* 21.0 ± 3.38* 4.00 ± 1.116 433 ± 69.7* 11.5 ± 2.78*
90-Day
0 10 4.3 ± 0.66 106 ± 18.2 23.9 ± 3.88 2.6 ± 0.49 51.3 ± 6.86 15.5 ± 3.39
5% 10 5.4 ± 0.92* 703 ± 102.3* 37.1 ± 10.59* 2.9 ± 0.86 314 ± 54.1* 17.0 ± 6.77
Values represent mean ± SD, unless otherwise speciﬁed.
* Statistically signiﬁcant (p 6 0.05).
Table 13
Liver and serum vitamin levels.
EPG N Male Female
Liver vitamin
Aa (lg/g)
Liver vitamin
Eb (lg/g)
Serum vitamin
Dc (ng/mL)
Liver vitamin
Aa (lg/g)
Liver vitamin
Eb (lg/g)
Serum vitamin
Dc (ng/mL)
30-Day
0 g/kg bw/day 10 99.7 ± 15.65 14.6 ± 2.80 51.9 ± 8.97 213 ± 19.4 32.0 ± 3.21 59.1 ± 12.22
0.5 10 105 ± 22.10 12.2 ± 1.19* 52.3 ± 12.62 178 ± 10.3* 24.3 ± 2.00* 63.0 ± 16.12
1 10 93.8 ± 13.83 11.6 ± 1.40* 49.7 ± 11.84 188 ± 40.6* 23.2 ± 3.62* 48.8 ± 23.73
2 10 95.8 ± 14.04 10.2 ± 1.02* 47.7 ± 12.40 179 ± 21.9* 17.4 ± 2.03* 52.0 ± 12.66
5% 10 86.1 ± 10.29 8.76 ± 1.234* 44.4 ± 9.49 189 ± 21.6* 17.3 ± 4.17* 36.4 ± 8.18*
90-Day
0 g/kg bw/day 10 199 ± 33.4 14.3 ± 1.08 54.4 ± 12.15 320 ± 37.1 27.1 ± 4.63 64.3 ± 10.34
0.5 10 185 ± 23.6 12.4 ± 1.17* 48.6 ± 5.86 292 ± 32.5 21.2 ± 2.73 58.8 ± 11.78
1 10 182 ± 23.5 10.0 ± 1.12* 40.4 ± 6.66* 294 ± 40.5 18.5 ± 2.28* 62.5 ± 8.63
2 10 174 ± 21.4 9.05 ± 0.80* 44.0 ± 9.47* 272 ± 17.6* 17.1 ± 2.19* 55.9 ± 11.87
5% 10 162 ± 32.2* 9.09 ± 1.50* 39.1 ± 8.58* 247 ± 24.1* 14.1 ± 1.72* 40.1 ± 11.27*
a Trans-retinol.
b a-Tocopherol.
c 25-OH Vitamin D.
* Statistically signiﬁcant (p 6 0.05).
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is important to note that, despite lower vitamin levels, animals in
this study did not exhibit any clinical signs of deﬁciency (e.g., slow
growth, skeletal muscle degeneration, improper bone calciﬁcation)
or toxicity to any organ system. Longer-term studies (e.g., rat 2-
years study, unpublished) have shown similar effects on fat soluble
vitamins with no clinical or histopathological evidence of vitamin
deﬁciency (i.e., adequate vitamin status over lifetime exposure).
Based on the results of this study, it was not possible to estab-
lish a no-observable-effect level (NOEL). The possible effect of EPG
on vitamin levels alone, in the absence of any clinical signs of deﬁ-
ciency, was not considered ‘‘adverse’’ per se. As such, the 2 g/kg bw/
day and 5% EPG level were considered to be no-observable-
adverse-effect levels (NOAELs).
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